Skip to content
Brilliant Blue Biosciences logoBrilliant BlueBiosciences
Articles

Papers, explained in our own words

Every entry summarises what the study set out to test, what it found and why it changes how we design delivery systems. Browse research and reviews or search the collection.

721 articles

Showing 1–13 of 13 articles · Keyword: Targeted delivery Clear keyword

Materials today. Bio2026ResearchNon-viral Gene DeliveryDrug Delivery

1. Reprogrammed macrophage-derived nanovesicle-lipid nanoparticle hybrids for cardiac siRUNX1 delivery: Therapeutic evaluation in Ang II-induced cardiac remodeling

Lee J, Mun D, Kang Jy, Yoo G, Park M, Chung S, Et Al.

Targeted delivery of small interfering RNA (siRNA) to the heart remains challenging because conventional lipid nanoparticles (LNPs) predominantly accumulate in the liver following systemic administration. To improve cardiac siRNA delivery, we developed a biomimetic hybrid nanoplatform by co-extruding siRUNX1-loaded…

Read the article
Current pharmaceutical design2026ResearchDrug Delivery

2. Rivastigmine and Emerging Nanotechnological Strategies for Targeted Delivery: A Comprehensive Review

Babar E, Ur Rehman A, Gul P, Arshad Ms, Shah Ba, Ahmed N

Alzheimer's disease affects millions of people globally; it is an irreversible and incurable disease, characterized by gradual cognitive decline as well as pathophysiological changes including the presence of senile plaques and neurofibrillary tangles. There are several risk factors associated with Alzheimer's…

Read the article
ACS applied materials & interfaces2026ResearchNon-viral Gene DeliveryDrug Delivery

3. Integration of Charged Peptide Amphiphiles within Lipid Nanoparticles (LNPs) for Enhanced Targeted mRNA Delivery

Yuan Y, Li G, Liu Y, Liu L, Hu C, Qi H, Et Al.

Lipid nanoparticles (LNPs) play a pivotal role in mRNA-based therapy; however, achieving targeted delivery remains challenging. We developed an LNP platform integrating peptide amphiphiles (PAs) to exploit their dual bioactivity and electrostatic tunability. Two PAs, cationic C16TAT (derived from a cell-penetrating…

Read the article
Nanoscale2019ResearchNon-viral Gene Delivery

4. Role of Apolipoprotein- and Vitronectin-Enriched Protein Corona on Lipid Nanoparticles for In Vivo Targeted Delivery and Transfection of Oligonucleotides in Murine Tumor Models

Dongyu Chen, Neha Parayath, Shanthi Ganesh, Weimin Wang, Mansoor Amiji

The protein corona that forms on lipid nanoparticles (LNPs) after systemic administration can alter their biological identity, but its impact on tumour delivery is not well understood. This study aimed to determine whether LNP formulation composition and surface charge can manipulate the protein corona and thereby…

Read the article
Nanoscale2019ResearchNon-viral Gene Delivery

5. Role of Surface Chemistry on Serum Protein Corona-Mediated Cellular Delivery and Gene Silencing with Lipid Nanoparticles

Dongyu Chen, Shanthi Ganesh, Weimin Wang, Mansoor Amiji

Protein corona formation in biological fluids can alter nanoparticle cellular uptake, transfection, and gene silencing, but the relationship between LNP surface chemistry and corona-mediated delivery is incompletely understood. This study examined how PEG lipid chain length and PEG molar ratio affect protein corona…

Read the article
Colloids and Surfaces B: Biointerfaces2018ResearchDrug Delivery

6. A novel MUC1 aptamer-modified PLGA-epirubicin-PβAE-antimir-21 nanocomplex platform for targeted co-delivery of anticancer agents in vitro and in vivo

Amirhossein Bahreyni, Mona Alibolandi, Mohammad Ramezani, Atefeh Sarafan Sadeghi, Khalil Abnous, Seyed Mohammad Taghdisi

Conventional chemotherapy for breast and colon cancers suffers from low specificity, rapid drug clearance, and severe toxic side effects on healthy tissues, while chemoresistance and metastasis remain major causes of cancer-related mortality. There is an unmet need for targeted delivery systems that can co-deliver…

Read the article
Nature Communications2017ResearchNon-viral Gene Delivery

7. T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity

Daniela Schmid, Chun Gwon Park, Christina A. Hartl, Nikita Subedi, Adam N. Cartwright, Regina Bou Puerto, Yiran Zheng, James Maiarana, Gordon J. Freeman, Kai W. Wucherpfennig, Darrell J. Irvine, Michael S. Goldberg

Systemic immune stimulation for cancer immunotherapy is associated with autoimmune-type pathologies, as the doses required to break immune tolerance can invoke undesired host-vs.-host effects. Targeting endogenous immune cell subsets in the circulation—which actively migrate into tumours—could concentrate…

Read the article
Journal of Biomedical Nanotechnology2016ResearchNon-viral Gene Delivery

8. Targeted Delivery of MicroRNA125a-5p by Engineered Lipid Nanoparticles for the Treatment of HER2 Positive Metastatic Breast Cancer

Stephen L. Hayward, David M. Francis, Parviz Kholmatov, Srivatsan Kidambi

miRNA-based therapeutics are limited by instability, poor cellular uptake, lack of targeting, and potential immune activation. No nonviral miRNA delivery strategy had been explored as a standalone treatment for HER2-positive metastatic breast cancer. HA-LNP uptake was significantly higher than naked FITC-dextran and…

Read the article
Biomaterials2014ResearchNon-viral Gene Delivery

9. Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8+ T cell response: A comparative study

Luis J. Cruz, Rodney A. Rosalia, Jan Willem Kleinovink, Felix Rueda, Clemens W.G.M. Löwik, Ferry Ossendorp

Dendritic cell (DC)-based therapies have shown clinical benefits but are hampered by labour-intensive, GMP-regulated vaccine preparations requiring multiple steps and donor variability. In vivo targeting of antigens to DC surface receptors using nanoparticle delivery systems could circumvent these drawbacks. However…

Read the article
Journal of Controlled Release2012ResearchNon-viral Gene Delivery

10. E-selectin liposomal and nanotube-targeted delivery of doxorubicin to circulating tumor cells

Hughes Ad, King Mr

Metastasis is the leading cause of cancer mortality, and circulating tumour cells (CTCs) are key to metastatic spread. Doxorubicin (DXR) is effective but systemically toxic and nonspecific. A targeted delivery system was needed to capture and kill CTCs under physiologically relevant flow while reducing off-target…

Read the article
Biomaterials2011ResearchNon-viral Gene Delivery

11. Polyethylenimine-grafted copolymer of poly(L-lysine) and poly(ethylene glycol) for gene delivery

Dai J, Zou S, Pei Y, Cheng D, Ai H, Shuai X

PEI is an effective gene carrier but high-molecular-weight PEI is nonbiodegradable and cytotoxic; PLL is biodegradable but lacks proton-buffering capacity, has low transfection efficiency, and is also cytotoxic. A vector combining the complementary strengths of PEI and PLL is needed. Cytotoxicity: At 100 µg/mL, PPL…

Read the article
Clinical Cancer Research2010ResearchNon-viral Gene Delivery

12. Targeted Gene Silencing Using RGD-Labeled Chitosan Nanoparticles

Han Hd, Mangala Ls, Lee Jw, Shahzad Mmk, Kim Hs, Shen D, Nam Ej, Mora Em, Stone Rl, Lu C, Lee Sj, Roh Jw, Nick Am, Lopez-Berestein G, Sood Ak

siRNA has therapeutic potential, but in vivo delivery is limited by rapid clearance, nuclease degradation, and nonspecific distribution. A tumour-targeted, biocompatible delivery system was needed to increase intratumoral siRNA accumulation, reduce off-target effects, and enable silencing of growth-promoting genes in…

Read the article
Biomaterials2005ResearchDrug Delivery

13. Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes

Norbert Dinauer, Sabine Balthasar, Carolin Weber, Jörg Kreuter, Klaus Langer, Hagen Von Briesen

Antibody-based therapeutics have shown promise in targeting specific cell types, but their efficacy can be enhanced by conjugation to drug carriers. Nanoparticles as drug carriers offer advantages including high drug loading capacity, controlled release, and protection from degradation. However, achieving selective…

Read the article
Articles | Brilliant Blue Biosciences